|
1
|
Hennessy BT, Coleman RL and Markman M:
Ovarian cancer. Lancet. 374:1371–1382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Takashima S, Kiyoto S, Takahashi M, Hara
F, Aogi K, Ohsumi S, Mukai R and Fujita Y: Clinical experience with
nanoparticle albumin-bound paclitaxel, a novel taxane anticancer
agent, and management of adverse events in females with breast
cancer. Oncol Lett. 9:1822–1826. 2015.PubMed/NCBI
|
|
3
|
Coderch C, Morreale A and Gago F:
Tubulin-based structure- affinity relationships for antimitotic
Vinca alkaloids. Anticancer Agents Med Chem. 12:219–225. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koontz MZ, Horning SJ, Balise R, Greenberg
PL, Rosenberg SA, Hoppe RT and Advani RH: Risk of therapy-related
secondary leukemia in Hodgkin lymphoma: The Stanford University
experience over three generations of clinical trials. J Clin Oncol.
31:592–598. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin XC and Cao Y: Advances in the
regulation of the rignals on Op18/stathmin. Life Science Res.
11:195–999. 2007.
|
|
6
|
Lin XC, Liao Y, Yang J, Su L, Zou H, Zuo Y
and Zou L: Regulation of the drug resistance of carcinoma cells
mediated by Op18/stathmin. Chem Life. 33:265–268. 2013.
|
|
7
|
Nemunaitis J: Stathmin 1: A protein with
many tasks. New biomarker and potential target in cancer. Expert
Opin Ther Targets. 16:631–634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin X, Liao Y, Xie J, Liu S, Su L and Zou
H: Op18/stathmin is involved in the resistance of Taxol among
different epithelial carcinoma cell lines. Cancer Biother
Radiopharm. 29:376–386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin X, Liao Y, Chen X, Long D, Yu T and
Shen F: Regulation of oncoprotein 18/stathmin signaling by ERK
concerns the resistance to Taxol in non-small cell lung cancer
cells. Cancer Biother Radiopharm. 31:37–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin X, Tang M, Tao Y, Li L, Liu S, Guo L,
Li Z, Ma X, Xu J and Cao Y: Epstein-Barr virus-encoded LMP1
triggers regulation of the ERK-mediated Op18/stathmin signaling
pathway in association with cell cycle. Cancer Sci. 103:993–999.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gupta KK, Li C, Duan A, Alberico EO, Kim
OV, Alber MS and Goodson HV: Mechanism for the
catastrophe-promoting activity of the microtubule destabilizer
Op18/stathmin. Proc Natl Acad Sci USA. 110:20449–20454. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hsu HP, Li CF, Lee SW, Wu WR, Chen TJ,
Chang KY, Liang SS, Tsai CJ and Shiue YL: Overexpression of
stathmin 1 confers an independent prognostic indicator in
nasopharyngeal carcinoma. Tumour Biol. 35:2619–2629. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Trovik J, Wik E, Stefansson IM,
Marcickiewicz J, Tingulstad S, Staff AC, Njolstad TS, Vandenput I,
Amant F, Akslen LA, et al: MoMaTec Study Group: Stathmin
overexpression identifies high-risk patients and lymph node
metastasis in endometrial cancer. Clin Cancer Res. 17:3368–3377.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Werner HM, Trovik J, Halle MK, Wik E,
Akslen LA, Birkeland E, Bredholt T, Tangen IL, Krakstad C and
Salvesen HB: Stathmin protein level, a potential predictive marker
for taxane treatment response in endometrial cancer. PLoS One.
9:e901412014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vancompernolie K, Boonefaes T, Mann M,
Fiers W and Grooten J: Tumor necrosis factor-induced microtubule
stabilization mediated by hyperphosphorylated oncoprotein 18
promotes cell death. J Biochem. 275:3876–3882. 2000.
|
|
16
|
Alli E, Yang JM, Ford JM and Hait WN:
Reversal of stathmin- mediated resistance to paclitaxel and
vinblastine in human breast carcinoma cells. Mol Pharmacol.
71:1233–1240. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin X, Yu T, Zhang LX, Chen SY, Chen X,
Liao Y, Dan L and Shen F: Silencing Op18/stathmin by RNA
interference promotes the sensitivity of nasopharyngeal carcinoma
cells to taxol and high grade differentiation of xenografted
tumours in nude mice. Basic Clin Pharmacol. 2016. View Article : Google Scholar
|
|
18
|
Tournebize R, Andersen SSL, Verde F, Dorée
M, Karsenti E and Hyman AA: Distinct roles of PP1 and PP2A-like
phosphatases in control of microtubule dynamics during mitosis.
EMBO J. 16:5537–5549. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hayden MS and Ghosh S: NF-κB, the first
quarter-century: Remarkable progress and outstanding questions.
Genes Dev. 26:203–234. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoesel B and Schmid JA: The complexity of
NF-κB signaling in inflammation and cancer. Mol Cancer. 12:862013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu Y, Liu C, Cheng H, Xu Y, Jiang J, Xu J,
Long J, Liu L and Yu X: Stathmin, interacting with Nf-κB, promotes
tumor growth and predicts poor prognosis of pancreatic cancer. Curr
Mol Med. 14:328–339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Itakura E, Huang RR, Wen DR, Paul E,
Wünsch PH and Cochran AJ: IL-10 expression by primary tumor cells
correlates with melanoma progression from radial to vertical growth
phase and development of metastatic competence. Mod Pathol.
24:801–809. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mahipal A, Terai M, Berd D, Chervoneva I,
Patel K, Mastrangelo MJ and Sato T: Tumor-derived interleukin-10 as
a prognostic factor in stage III patients undergoing adjuvant
treatment with an autologous melanoma cell vaccine. Cancer Immunol
Immunother. 60:1039–1045. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Danoch H, Kalechman Y, Albeck M, Longo DL
and Sredni B: Sensitizing B- and T- cell lymphoma cells to
paclitaxel/abraxane-induced death by AS101 via inhibition of the
VLA-4-IL10-survivin axis. Mol Cancer Res. 13:411–422. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moldoveanu T, Follis AV, Kriwacki RW and
Green DR: Many players in BCL-2 family affairs. Trends Biochem Sci.
39:101–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Delbridge ARD, Grabow S, Strasser A and
Vaux DL: Thirty years of BCL-2: Translating cell death discoveries
into novel cancer therapies. Nat Rev Cancer. 16:99–109. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alli E, Bash-Babula J, Yang JM and Hait
WN: Effect of stathmin on the sensitivity to antimicrotubule drugs
in human breast cancer. Cancer Res. 62:6864–6869. 2002.PubMed/NCBI
|
|
28
|
Purani I, Tejada A and Mistry SJ: Effects
of combination of microtubule depolymerizing peptides and
vinblastine in breast cancer. Cancer Res. 73:(Suppl 8). S3275.
2013. View Article : Google Scholar
|
|
29
|
Nishio K, Nakamura T, Koh Y, Kanzawa F,
Tamura T and Saijo N: Oncoprotein 18 overexpression increases the
sensitivity to vindesine in the human lung carcinoma cells. Cancer.
91:1494–1499. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Devred F, Tsvetkov PO, Barbier P, Allegro
D, Horwitz SB, Makarov AA and Peyrot V: Stathmin/Op18 is a novel
mediator of vinblastine activity. FEBS Lett. 582:2484–2488. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Malesinski S, Tsvetkov PO, Kruczynski A,
Peyrot V and Devred F: Stathmin potentiates vinflunine and inhibits
Paclitaxel activity. PLoS One. 10:e01287042015. View Article : Google Scholar : PubMed/NCBI
|
